Very rapid virologic response and early HCV response kinetics, as quick measures to compare efficacy and guide a personalized response-guided therapy
Mostafa Yakoot, Alaa M Abdo, Ahmed Yousry, Sherine Helmy, Mostafa Yakoot, Alaa M Abdo, Ahmed Yousry, Sherine Helmy
Abstract
Background: This is the second and final report for our study designed to compare two generic sofosbuvir products for the degree and speed of virologic response to a dual anti-hepatitis C virus (HCV) treatment protocol. We aimed to test the applicability of the early virus response kinetics and the very rapid virologic response (vRVR) rate as quick outcome measures for accelerated comparative efficacy studies and as a foundation for a personalized response-guided therapy.
Methods: Fifty eligible chronic HCV patients were randomized to either one of two generic sofosbuvir products (Gratisovir or Grateziano) at a daily dose of one 400 mg tablet plus a weight-based ribavirin dose. Data were compared between the groups for early virus response kinetics and vRVR rates in relation to the rates of final sustained virologic response at week 12 posttreatment (SVR12).
Results: The Log10 transformed virus load (Log polymerase chain reaction) curves showed fairly similar rapid decline during the first 2 weeks, with no significant difference between the groups at four analysis points throughout the study by repeated-measures factorial analysis of variance test (P=0.48). The SVR12 rates were 96% (95% confidence interval, 79.6%-99.9%) in Gratisovir group (24/25) and 95.7% (95% confidence interval, 78%-99.9%) in Grateziano group (22/23). There was no statistically significant difference found by exact test (P>0.999). There was a significant association between the vRVR and the SVR12, with 100% positive predictive value (38/38 of those who had vRVR, achieved a final SVR12) and 82.6% sensitivity (among the total 46 with SVR12, 38 were having vRVR).
Conclusion: We can conclude from our study that the early HCV response kinetics and the vRVR rates could be used as sensitive quick markers for efficacy (with a very high positive predictive value for SVR12), based on our accelerated comparative efficacy research model. This might open the way for new models of accelerated equivalence efficacy studies along with the bioequivalence kinetics studies to test a generic drug against a reference. Also, the early response kinetics and the vRVR might be used as qualifiers for a personalized course of treatment. This could shorten unnecessarily long treatment courses in rapid responders and might help to avoid relapses in slow responders.
Keywords: HCV response kinetics; chronic hepatitis C; direct-acting antiviral agents; dual therapy; ribavirin; sofosbuvir; vRVR; very rapid virologic response.
Figures
References
- Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect. 2011;17(2):107–115.
- Guerra J, Garenne M, Mohamed MK, Fontanet A. HCV burden of infection in Egypt: results from a nationwide survey. J Viral Hepat. 2012;19(8):560–567.
- Schinazi R, Halfon P, Marcellin P, Asselah T. HCV direct-acting antiviral agents: the best interferon-free combinations. Liver Int. 2014;34(Suppl 1):69–78.
- Ferenci P, Laferl H, Scherzer TM, et al. Austrian Hepatitis Study Group Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology. 2008;135(2):451–458.
- Hoofnagle JH, Wahed AS, Brown RS, Jr, Howell CD, Belle SH, Virahep-C Study Group Early changes in hepatitis C virus (HCV) levels in response to peginterferon and ribavirin treatment in patients with chronic HCV genotype 1 infection. J Infect Dis. 2009;199(8):1112–1120.
- Esmat GE, Al Akel W, Abdel Aziz RA, et al. Hepatitis C viral kinetic changes in a retrospective cohort study of chronic hepatitis C virus Egyptian patients on pegylated interferon and ribavirin therapy. J Interferon Cytokine Res. 2016;36(3):149–158.
- Maasoumy B, Vermehren J, Welker MW, et al. Clinical value of on-treatment HCV RNA levels during different approved sofosbuvir-based antiviral regimens. J Hepatol. 2016 Apr 13; Epub.
- Kohli A, Kattakuzhy S, Sidharthan S, et al. Four-week direct-acting antiviral regimens in non-cirrhotic patients with hepatitis C virus genotype 1 infection: an open-label, nonrandomized trial. Ann Intern Med. 2015;163(12):899–907.
- Doss W, Shiha G, Hassany M, et al. Sofosbuvir plus ribavirin for treating Egyptian patients with hepatitis C genotype 4. J Hepatol. 2015;63(3):581–585.
- Yakoot M, Abdo AM, Yousry A, Helmy S. The very-rapid and the ultra-rapid virologic response to two treatment options in patients with chronic hepatitis C: an interim report of a prospective randomized comparative effectiveness study. Drug Des Devel Ther. 2015;9:6027–6033.
- Wedemeyer H, Jensen DM, Godofsky E, Mani N, Pawlotsky JM, Miller V, Definitions/Nomenclature Working Group of the HCV DrAG (HCV Drug Development Advisory Group), under the auspices of the Forum for Collaborative HIV Research Recommendations for standard-ized nomenclature and definitions of viral response in trials of hepatitis C virus investigational agents. Hepatology. 2012;56(6):2398–2403.
- AASLD/IDSA HCV Guidance Panel Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015;62(3):932–954.
- Dahari H, Canini L, Graw F, et al. HCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir. J Hepatol. 2016;64(6):1232–1239.
- Ruane PJ, Ain D, Stryker R, et al. Sofosbuvir plus ribavirin for the treatment of chronic genotype four hepatitis C virus infection in patients of Egyptian ancestry. J Hepatol. 2015;62(5):1040–1046.
Source: PubMed